23andMe Goes Global In Its Data-Mining Efforts
By Megan Molteni,
Wired
| 05. 18. 2018
Yanny or Laurel—could the secret to which word you hear be in your DNA? It’s a notion someone pitched at 23andMe headquarters Thursday, during the consumer genetics outfit’s annual Genome Research Day. (Spoiler: The company is not going to roll out a survey to see if the latest meme has a genetic component.)
The event—a sort of cross between a science fair and a recruiting booth—attracted more than 100 researchers to the company’s candy cane–colored lunchroom for a day of talks, poster presentations, and most importantly, information sessions about how to work with 23andMe’s consumer data riches.
23andMe has amassed more than 4 million genetic profiles from customers who’ve consented to be studied, one of the biggest genetic research resources in the US. And because most of those people fill out lots of surveys, each genetic profile comes attached to about 300 phenotypic data points—like how many cigarettes you’ve smoked during your lifetime or if anyone in your family has ever been diagnosed with mild cognitive impairment.
And while the company has doubled in size over the last two years...
Related Articles
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...